In the city of love, hearts were a-flutter with news of recent trial results and updates on the transcatheter aortic valve replacement (TAVR) device market. Physicians attending euroPCR 2013 showed a great deal of interest in TAVR-related sessions. In fact, TAVR learning sessions were standing room only, getting so crowded that at times conference employees were playing the role of a bouncer, letting one attendee into the room for every attendee that left. Trial presentations made it obvious that many companies are interested in obtaining a piece of the growing TAVR device market, but physicians made it clear that they do not expect the market to grow to resemble the European market for drug-eluting stents (DES). One physician asked, Do you think we really need 10 valves on the market and the panel moderating this particular section was quick to say no. TAVR is a more complicated procedure compared to placing a DES, and physicians may get to a point where they will be comfortable with 3 to 4 devices, but they don't expect there to be the same amount of room in the market for as many TAVR devices as we see DES. Who will end up on top remains to be seen, but one thing is clear: the TAVR device market will be one to watch.

DRG becomes Clarivate

View Now